Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Compounding is the practice of preparing a medication specifically for an individual patient based on a valid prescription
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E
Current development status (2024-2025) Phase 3 trials underway: TRIUMPH-1: Obesity without diabetes (enrolling) TRIUMPH-2: Obesity with type 2 diabetes TRIUMPH-3: Heart failure + obesity Multiple other indications exploring All trials must complete before FDA submission Timeline estimates: Uncertainty factors: Trial results (must show efficacy + safety) FDA review speed (standard vs priority) Manufacturing scale-up Eli Lilly's priorities Competition ( semaglutide / tirzepatide established) Realistically: 2-3 years minimum before FDA approval Could be longer if trials show issues Market availability 3-4+ years out Patience required See peptide research and studies for trial information
Xiao J et al
US$ 24.85
US$ 22.38
US$ 23.09
US$ 28.17
US$ 26.38
US$ 27.03
US$ 21.42
